Projects › Road to the Cure
Four laboratories on two continents, one question: which GIST cells survive the best drugs we have, and how do we remove them?
Central question 11: Why do some tumor cells survive treatment without being resistant, and how do we eliminate them?
First-line KIT/PDGFRA-inhibitors, imatinib and avapritinib, shrink most advanced GISTs, yet some tumor cells always survive (persist) and eventually cause resistance. Strikingly, the best response of most GIST metastases with acquired imatinib resistance is persistence rather than regression. Therefore, cures for both treatment-naïve and treatment-resistant GISTs require strategies that remove these persister cells.
KIT and PDGFRA oncogenic mutations induce GIST proliferation and survival in part through the PI3K/AKT and MEK/MAPK signaling pathways. Preliminary studies in clinical specimens show that GIST cells persisting during effective KIT/PDGFRA-inhibitor therapies depend on combinations of:
We hypothesize that insufficient blockade of the PI3K/AKT and MEK/MAPK pathways is a major roadblock to cures for metastatic GIST.
West German Cancer Center, University Hospital Essen · Essen, Germany
Large biobank and long clinical follow-up of patients treated over two decades, plus isogenic GIST cell lines covering many KIT and PDGFRA variants. Studies whether stronger KIT inhibition deepens cell kill, and how mutations downstream of KIT and their zygosity shape persistence. Leads the shared sample inventory, the joint omics database and a registry of response at surgery.
Memorial Sloan Kettering Cancer Center · New York, USA
Tumor-intrinsic and microenvironment mechanisms of adaptive resistance. Builds on the discovery of ETV1 and FOXF1 as lineage survival factors: screens for druggable regulators of FOXF1, single-cell and spatial profiling of responders and non-responders, and neoadjuvant combination trials with imatinib.
Perelman School of Medicine, University of Pennsylvania · Philadelphia, USA
Fresh tissue from surgery in untreated, responding and resistant GIST, with bulk and single-cell RNA sequencing. Develops immunotherapy to combine with kinase inhibitors, including preoperative trials, uses engineered mouse models of GIST, and explores steroid hormone receptors as non-kinase targets.
Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Harvard Medical School · Boston, USA
A repository of persistent metastases removed after long-term or neoadjuvant kinase-inhibitor therapy, compared with untreated and progressing tumors. Asks whether persistence mechanisms are the same across all lesions in a patient, and uses genome-wide functional screens, transcriptomics and phospho-proteomics to find new targets.
The program answers central questions 3, 4 and 11 and supplies the targets for the combinations that the platform trial will test. Its biobanks and isogenic cell lines are part of the model platform.
To collaborate with the program, please contact info@gistt-race.org.
“The most effective way to do it is to do it.”attributed to Amelia Earhart, aviation pioneer